This study is looking at how well a drug named isatuximab works with other new medicines in people with a type of cancer called *relapsed or refractory multiple myeloma (RRMM)*. Multiple myeloma is a cancer of plasma cells, which are a kind of white blood cell. Participants will continue treatment until their disease gets worse, they have bad side effects, or they decide to stop, for up to about 28 months.

Key Points:

• Duration: Up to 28 months or until disease progression.
• Eligibility: Must be 18 or older and have had at least two prior treatments for RRMM.
• Risks: Includes various health conditions and drug interactions; careful screening required.

To join, participants must meet certain conditions, like being 18 or older and having been treated for RRMM before. They also need to avoid certain health issues and medications to participate. The study is divided into six substudies, with different rules and treatments for each. Some substudies have specific health requirements, like not having certain infections or other health problems.